Targeting CD40 enhances antibody- and CD8-mediated protection against respiratory syncytial virus infection

Respiratory Syncytial Virus (RSV) infects almost all children under the age of one and is the leading cause of hospitalization among infants. Despite several decades of research with dozens of candidate vaccines being vigorously evaluated in pre-clinical and clinical studies, there is no licensed va...

Descripción completa

Detalles Bibliográficos
Autores principales: Muralidharan, Abenaya, Russell, Marsha, Larocque, Louise, Gravel, Caroline, Li, Changgui, Chen, Wangxue, Cyr, Terry, Lavoie, Jessie R., Farnsworth, Aaron, Rosu-Myles, Michael, Wang, Lisheng, Li, Xuguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226510/
https://www.ncbi.nlm.nih.gov/pubmed/30413743
http://dx.doi.org/10.1038/s41598-018-34999-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226510/
https://www.ncbi.nlm.nih.gov/pubmed/30413743
http://dx.doi.org/10.1038/s41598-018-34999-z

Ejemplares similares